#Shanghai #None #Pharmacokinetics #Viva Biotech #DMPK

Adventures in DMPK: Viva Biotech's Innovative Pharmacology Solutions

In the rapidly evolving field of drug development, understanding Pharmacokinetics and Pharmacodynamics (PKPD) has become vital as new drug modalities emerge. Viva Biotech is at the forefront of this evolution, having designed a comprehensive pharmacology platform that addresses a wide range of drug discovery needs. The company's recent webinar, titled 'Adventures in DMPK', featured insights from Dr. Justin Cui, Vice President of Pharmacology, showcasing their extensive capabilities in this area.

The Importance of a Holistic Approach

Pharmacokinetics (PK) involves the study of how drugs are absorbed, distributed, metabolized, and eliminated by the body, while Pharmacodynamics (PD) focuses on the biological effects of drugs. With these components becoming increasingly interconnected, Viva Biotech's integrated platform aims to streamline the drug development process from in vitro ADME (Absorption, Distribution, Metabolism, and Excretion) assays to in vivo efficacy studies.

During the session, Dr. Cui explained how methodologies for small molecules, peptides, and PROTACs (proteolysis-targeting chimeras) share a common framework. This framework includes physicochemical profiling, assessing metabolic stability, permeability testing, and evaluating drug-drug interaction risks. Notably, decision-making based on exposure metrics helps prioritize drug candidates effectively, ensuring potentially unsuccessful candidates are identified early in the process.

Tailored Solutions for Diverse Modalities

For peptide development, Viva Biotech adopts a cross-species pharmacokinetic design, facilitating studies across various administration routes like subcutaneous, intravenous, and intramuscular injections. Their robust metabolite profiling encompasses analyses of plasma, urine, bile, feces, and different tissues—empowering a thorough understanding of drug behavior in the body. This uniformity in analytical techniques allows for meaningful comparisons across drug modalities.

Turning to antibody programs, the company employs unique strategies, particularly by focusing on the role of the neonatal Fc receptor (FcRn) in pharmacokinetics. Their technological advancement includes a custom-engineered hFcRn/B2M-MDCK Transwell system, which evaluates transcytosis in a cost-effective manner. This innovation provides significant data correlations to support the prediction of clinical outcomes, demonstrating a robust method for early candidate evaluation before entering in vivo phases.

Enhancing DMPK Decisions with Mechanistic Insights

The integration does not cease at pharmacokinetics. The webinar underlined the significance of pairing DMPK conclusions with mechanistic bioassays to improve decision-making. Viva Biotech’s immunology portfolio addresses immune cell responses and interactions through advanced assays such as multi-color flow cytometry and cytokine profiling. These technologies are complemented by in vivo tumor efficacy evaluations utilizing various models, thus bridging the gap between PK data and real-world biological responses.

Through these collective efforts, Viva Biotech has cultivated a reputation for excellence in drug discovery. With over a decade of experience, their commitment to enhancing pharmacological capabilities continues to grow—reinforced by infrastructural expansions and an increasingly integrated approach that works across therapeutic domains, including oncology, autoimmune diseases, and metabolic disorders.

Conclusion: A One-Stop DMPK Solution

In essence, Viva Biotech is redefining the DMPK landscape as they successfully merge multiple drug modalities within a unified service model. This model adeptly connects structure-based discovery with critical elements like ADME evaluations, pharmacokinetics, pharmacology insights, toxicology testing, and regulatory IND filings. The result is a more informed approach to drug development, allowing for data-driven decisions during the crucial preclinical stages. For further details on their pharmacology and DMPK services, visit their official site Viva Biotech.